These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 30005982)
1. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. Ruiz J; Miller AA; Tooze JA; Crane S; Petty WJ; Gajra A; Klepin HD J Geriatr Oncol; 2019 Jan; 10(1):48-54. PubMed ID: 30005982 [TBL] [Abstract][Full Text] [Related]
2. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer. Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664 [TBL] [Abstract][Full Text] [Related]
3. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials. Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861 [TBL] [Abstract][Full Text] [Related]
4. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer. Tas F; Yildiz I; Kilic L; Ciftci R; Keskin S; Sen F Am J Ther; 2016; 23(3):e670-9. PubMed ID: 23782755 [TBL] [Abstract][Full Text] [Related]
5. Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer. Brooks GA; Austin AM; Uno H; Dragnev KH; Tosteson ANA; Schrag D JAMA Netw Open; 2018 Oct; 1(6):e183023. PubMed ID: 30646220 [TBL] [Abstract][Full Text] [Related]
6. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC). Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016). Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074 [TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330 [TBL] [Abstract][Full Text] [Related]
9. [Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel Administrated Every Three Weeks in Inoperable Advanced Non-small Cell Lung Cancer: A Retrospective Study from A Single Center]. Zhao J; Zhang X; Hu K; Wang H; Xu Y; Si X; Zhong W; Huang X; Zhang L; Wang M Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):731-737. PubMed ID: 27866515 [TBL] [Abstract][Full Text] [Related]
10. Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study. Shiroyama T; Tamiya M; Minami S; Takata S; Masuhiro K; Futami-Nishijima Y; Uenami T; Mori M; Koba T; Matsuki T; Takimoto T; Suzuki H; Okamoto N; Komuta K; Hirashima T; Kumanogoh A; Kijima T Cancer Chemother Pharmacol; 2017 Sep; 80(3):461-467. PubMed ID: 28688052 [TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655 [TBL] [Abstract][Full Text] [Related]
12. Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. Ramalingam SS; Blais N; Mazieres J; Reck M; Jones CM; Juhasz E; Urban L; Orlov S; Barlesi F; Kio E; Keiholz U; Qin Q; Qian J; Nickner C; Dziubinski J; Xiong H; Ansell P; McKee M; Giranda V; Gorbunova V Clin Cancer Res; 2017 Apr; 23(8):1937-1944. PubMed ID: 27803064 [No Abstract] [Full Text] [Related]
13. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559 [TBL] [Abstract][Full Text] [Related]
15. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study. Rozzi A; Nardoni C; Corona M; Restuccia MR; Falbo T; Lanzetta G J Chemother; 2010 Dec; 22(6):419-23. PubMed ID: 21303751 [TBL] [Abstract][Full Text] [Related]
16. A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. Chen YM; Perng RP; Tsai CM; Whang-Peng J J Thorac Oncol; 2006 Feb; 1(2):141-5. PubMed ID: 17409843 [TBL] [Abstract][Full Text] [Related]
17. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. Govindan R; Szczesna A; Ahn MJ; Schneider CP; Gonzalez Mella PF; Barlesi F; Han B; Ganea DE; Von Pawel J; Vladimirov V; Fadeeva N; Lee KH; Kurata T; Zhang L; Tamura T; Postmus PE; Jassem J; O'Byrne K; Kopit J; Li M; Tschaika M; Reck M J Clin Oncol; 2017 Oct; 35(30):3449-3457. PubMed ID: 28854067 [TBL] [Abstract][Full Text] [Related]
18. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer. Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333 [TBL] [Abstract][Full Text] [Related]
19. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer. Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800 [TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial. Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]